Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
The Rat PAI1 (Plasminogen Activator Inhibitor 1) ELISA quantitates PAI1 in serum and plasma.
原理方法
The Rat Plasminogen Activator Inhibitor 1 (PAI1) solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the concentration of Plasminogen Activator Inhibitor 1 (PAI1) in biological samples. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are added into these wells and bind to the immobilized (capture) antibody.
The sandwich complex is formed by the addition of a second (HRP-linked) detection antibody specific to Plasminogen Activator Inhibitor 1 (PAI1). Excess reagents are washed from the plate.
A substrate solution is added that reacts with the enzyme-antibody-target complex to produce a measurable signal. The enzyme-substrate reaction is terminated by the addition of stop solution. The intensity of the signal, measured spectrophotometrically at 450 ± 2 nm, is directly proportional to the concentration of Plasminogen Activator Inhibitor 1 (PAI1) present in the original specimen.
Rigorous validation:
Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
PAI1 (plasminogen activator inhibitor 1) belongs to serine protease inhibitor superfamily, and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA). Platelets are the main source of the circulating PAI11, but it is synthesized and secreted by many tissue and cell types, including fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells. Expression of PAI11 can be regulated at the transcriptional level by many factors including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and other environmental or physical factors. PAI1 is present at increased levels in various disease states, and has been linked to an increased occurrence of thrombosis in obesity, thrombophilia and the metabolic syndrome. Defects in PAI-1 are characterized by abnormal bleeding. PAI1 mediates inhibition of fibrinolysis by inhibiting the activity of plasminogen activator, and may promote neuronal survival. Other defects in PAI1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency). Alternatively spliced transcript variants encoding different isoforms of PAI1 have been found.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
基因别名 : Pai1, PAI1A, Pai1aa, Planh, Planh1, RATPAI1A, Serpine1
基因ID : (Rat) 24617
基因符号 : Serpine1
蛋白别名 : Endothelial plasminogen activator inhibitor, PAI, PAI-1, plas, SERPINE-1, Plasminogen activator inhibitor 1, serine (or cysteine) peptidase inhibitor, clade E, member 1, serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), Serpin E1
UniProt ID (Rat) P20961